UCL Technology Fund invests in IGEM Therapeutics

30 November 2018

UCLTF has invested in a series A round for immuno-oncology company IGEM Therapeutics. The £5million funding round also included investment from Alsa Holdings and Epidarex Capital. The funding will enable IGEM Thereapeutics to further develop its portfolio of IgE antibody candidates against a variety of cancers.

Read more from this story here: UCLTF

2018-11-30T14:27:32+00:00